The China diabetes market size reached a value of almost USD 4.73 Billion in the year 2024. The market is further expected to grow at a CAGR of 9.50% between 2025 and 2034 to reach a value of almost USD 11.72 Billion by 2034.

The China Diabetes Care Drugs and Devices Market is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

The China Diabetes Drugs Market Report is Segmented by Drug Class (Insulins, Oral Anti-Diabetics, Non-Insulin Injectable Drugs, Combination Drugs), Diabetes Type (Type-1 and Type-2 Diabetes), Drug Origin (Branded and Generic / Biosimilar), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and O2O Platforms). The Market Forecasts are Provided in Terms of Value (USD).

In 2021, the market size of the diabetes medication sector in China was estimated to be about ** billion yuan and was set to expand further in 2022. The market growth would be driven by the rise in diabetes cases, the increasing consumer health spending, as well as the positive changes in healthcare policies and programs such as Healthy China 2030.

China’s diabetes drug landscape

Currently, the antidiabetic drug industry in China is dominated by oral hypoglycemic medications (for type 2 diabetes). Acarbose has become the most popular oral antidiabetic drug, owing its effectiveness to the reduction of glucose uptake, which is particularly suitable for the high-carbohydrate Chinese diet. Another diabetes medication type is human insulin and its analogues – mainly used among all type 1 diabetes cases and some people with type 2 diabetes or gestational diabetes. Short-acting insulin aspart and long-acting glargine controlled the major Chinese market for human insulin and insulin analogues in 2018. Medical experts forecasted that glucagon-like peptide * receptor agonists (GLP-1 RAs) - a more convenient non-insulin option with other health benefits – would see a drastic sales growth in China.

The front runners: Novo Nordisk and Bayer

Global top diabetes drug manufacturers, like Novo Nordisk, Eli Lilly, Sanofi, and Bayer, had tapped into the massive Chinese market. When it comes to the brand popularity, the German pharmaceutical firm Bayer has been well-known with its Glucobay® - an acarbose product – winning the bestselling spot in China for the past few years. However, its rival Novo Nordisk has grabbed a significant portion of the insulin and GLP-1 market. The world leader in diabetes care earned over **** billion Danish kroner (about **** billion U.S. dollars) from its business in Greater China. Global heavyweights would retain their dominance in the Chinese diabetes medication sector. It would take some years for domestic players like Huangdong Medicine and Gan & Lee Pharmaceutical to gain some tractions in the market.

The China Diabetes Devices Market Report is Segmented Into Device Category (Management Devices and Monitoring Devices), End User (Hospital and Clinics, Home-Care Settings, Retail Pharmacies & Diabetes Centers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce / Online Pharmacies). The Market Provides the Value (in USD) and (in Units) for the Above-Mentioned Segments.

The size of the China Diabetes Drugs And Devices market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 3.50% during the forecast period.Diabetes drugs and devices are the tools to manage and control diabetes, this chronic disease that is associated with high levels of blood sugar. They help in controlling insulin production, improve the sensitivity of body cells to insulin, and decrease blood glucose levels directly. Multiple categories of these drugs include oral antidiabetic drugs, newer classes of drugs, GLP-1 receptor agonists, and SGLT-2 inhibitors.Diabetes technologies, to its contrast, may assist an individual with diabetes in monitoring and managing glucose levels in the blood. These include a blood glucose meter, continuous glucose monitoring system, insulin pump, and pen injector. These machines provide patients with actual information regarding their real blood sugar level, thereby allowing them to make proper decisions regarding food intake, exercise, and drug therapy.The market for diabetes drugs and devices in China is one of the largest and fastest-growing in the world.The high growth rate of diabetes patients along with increased health care and access to healthcare has faced great demands for such products. Even further growth in the market has been driven by the Chinese government control over diabetes through various initiatives like the National Diabetes Prevention and Control Program. This demand for drugs and devices in the treatment of diabetes is further elevated by an increasingly old demographic across the Chinese population, which is becoming more sedentary. Recent developments include: April 2023: The National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., June 2022: LifeScan announced that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) has published Real World Evidence of Improved Glycemic Control in People with Diabetes using a Bluetooth-connected Blood Glucose Meter with Mobile Diabetes Management Application using the OneTouch Reveal mobile app with the OneTouch Verio Reflect meter- synced via Bluetooth wireless technology could support improved glycemic control for people with diabetes.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: Continuous Glucose Monitoring Segment Expected to Witness the Highest Growth Rate Over the Forecast Period.

The China diabetes treatment market, valued at approximately $12.34 billion in 2025, exhibits a Compound Annual Growth Rate (CAGR) of 2.70% from 2025 to 2033. This growth is fueled by several key factors. The rising prevalence of diabetes in China, driven by an aging population, increasing urbanization, and lifestyle changes including sedentary habits and poor diets, is a primary driver. Furthermore, increasing awareness of diabetes and improved access to healthcare, particularly in urban areas, are contributing to higher diagnosis rates and treatment adoption. The market is segmented across various drug classes, including insulins (basal/long-acting, bolus/fast-acting, human insulins, and biosimilars), oral anti-diabetic drugs (biguanides, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and dopamine D2 receptor agonists), and non-insulin injectables (GLP-1 receptor agonists and amylin analogues). Competition is fierce amongst major pharmaceutical companies such as Novo Nordisk, Sanofi, Eli Lilly, and Merck, each vying for market share with their diverse portfolios of innovative and established therapies. While the market shows positive growth, challenges remain. These include affordability concerns, especially in rural areas, and the need for improved patient education and adherence to treatment regimens. Future market growth will likely depend on the development and adoption of newer, more effective treatments, pricing strategies that cater to the diverse socioeconomic landscape of China, and continued investment in diabetes prevention and management initiatives. The projected market expansion is expected to be driven primarily by the increasing adoption of newer drug classes, such as SGLT-2 inhibitors and GLP-1 receptor agonists, which offer improved efficacy and safety profiles compared to older treatments. The continued introduction of biosimilars will also contribute to market growth by offering more affordable insulin options. However, the growth trajectory will also be influenced by government healthcare policies, including price controls and reimbursement strategies. Further segmentation analysis would reveal the relative market share of each drug class and the dominance of specific brands within those segments. Understanding the regional variations in diabetes prevalence and access to healthcare will be crucial for strategic market positioning and investment decisions. This necessitates an ongoing monitoring of the evolving regulatory landscape and patient needs to accurately predict future market trends and opportunities. Recent developments include: April 2023: National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., October 2022: Hua Medicine announced that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator developed by the Company, was officially approved by the National Medical Products Administration (NMPA) of China. It is to be used as monotherapy for drug naïve Type 2 diabetes patients or combined with metformin in metformin-tolerated Type 2 diabetes to control blood glucose levels.. Notable trends are: The oral anti-diabetic drugs segment holds the highest market share in the China Diabetes Care Drugs Market in the current year.

The size of the China Diabetes Devices Market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.66% during the forecast period.Diabetes devices are medical tools which can be used by people diagnosed with diabetes to manage blood sugar. It includes very important monitoring, delivery of insulin, and diabetes management as a whole.Commonly used types of diabetes devices include:Blood Glucose Meters: These are devices which determine the blood sugar levels using the analysis of a small amount of blood sample.Continuous Glucose Monitoring (CGM) Systems: These systems continue monitoring the blood sugar levels with a small sensor placed under the skin.Insulin pumps: These are devices for delivering insulin through a thin tube inserted under the skin to provide more precise insulin delivery in comparison to injections.Insulin pens: pre-filled pens that deliver a predetermined dose of insulin with an injection.The China diabetes devices market is one of the largest and fastest-growing in the world. Growing cases of diabetes, along with higher disposable incomes and better access to healthcare, have created an ever-growing demand for the devices. The Chinese government initiatives to control diabetes, especially the National Diabetes Prevention and Control Program, have accelerated growth in the market. This market is expected to continue rising due to the aging population in China and increasingly sedentary lifestyles. Recent developments include: February 2023: The MiniMed670G BLE, developed by Medtronic MiniMed, has received approval from the China NMPA. This advanced product includes an insulin pump kit, transmitter kit, and glucose sensor. It incorporates two key technologies: a hybrid closed-loop algorithm for auto mode and electrochemical impedance spectroscopy technology to monitor sensor status, ensuring accurate glucose readings., June 2022: LifeScan revealed a significant development as the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) published Real World Evidence showcasing improved glycemic control in individuals with diabetes. This positive outcome is attributed to the utilization of a Bluetooth-connected Blood Glucose Meter in conjunction with a Mobile Diabetes Management Application. The OneTouch Reveal mobile app, paired with the OneTouch Verio Reflect meter via Bluetooth wireless technology, emerges as a pivotal tool supporting enhanced glycemic control for those managing diabetes.. Key drivers for this market are: Increasing Incidence of Hematologic Cancer, Growing Demand for Personalized Therapy. Potential restraints include: Unfavorable Reimbursement Scenario. Notable trends are: Monitoring Devices Market is growing with the highest CAGR in forecast period.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 re

In December 2023, the Danish pharmaceutical company Novo Nordisk controlled more than half of the insulin market in China, in terms of sales volume. Founded in 1923, the firm specializes in producing diabetes medications, which accounted for around ** percent of its annual sales revenue in 2023.

The China diabetes drugs and devices market is a rapidly expanding sector, projected to reach a substantial size driven by several key factors. The market's Compound Annual Growth Rate (CAGR) exceeding 3.50% from 2019-2033 indicates significant and sustained growth. This expansion is fueled by the rising prevalence of diabetes in China, an aging population increasing susceptibility to the disease, and improving healthcare infrastructure leading to better diagnosis and management. Increased awareness campaigns and improved access to advanced therapies, such as continuous glucose monitoring (CGM) devices and insulin pumps, are also contributing to market growth. The market segmentation reveals strong performance across both devices and drugs. Within devices, continuous glucose monitoring and insulin pump segments show particularly strong growth potential due to their improved convenience and efficacy compared to traditional methods. In the drug segment, oral anti-diabetes drugs, insulin drugs, and combination therapies dominate, with ongoing research and development leading to the introduction of newer, more effective medications. Competition is fierce, with major international players like Novo Nordisk, Medtronic, and Sanofi alongside significant domestic players shaping the market landscape. However, challenges remain. The high cost of advanced diabetes management technologies and medications presents a barrier to access for many patients, particularly in rural areas. This necessitates a focus on affordable solutions and effective healthcare policies to ensure wider accessibility and equitable distribution of treatments. Furthermore, potential regulatory hurdles and variations in reimbursement policies across different regions within China can impact market growth and profitability for companies operating in the sector. The market will likely see further consolidation as larger players seek to acquire smaller companies and expand their market share, leading to intensified competition and a need for ongoing innovation and differentiation strategies. The forecast for the market remains positive, with continued growth expected throughout the projection period, particularly in the segments offering technologically advanced solutions and cost-effective options. Recent developments include: April 2023: The National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., June 2022: LifeScan announced that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) has published Real World Evidence of Improved Glycemic Control in People with Diabetes using a Bluetooth-connected Blood Glucose Meter with Mobile Diabetes Management Application using the OneTouch Reveal mobile app with the OneTouch Verio Reflect meter- synced via Bluetooth wireless technology could support improved glycemic control for people with diabetes.. Notable trends are: Continuous Glucose Monitoring Segment Expected to Witness the Highest Growth Rate Over the Forecast Period.

The size of the China Diabetes Treatment Industry market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 2.70% during the forecast period.Diabetes treatment includes management of a chronic condition indicated by high blood sugar levels in the body. The principle objectives of diabetes treatment encompass healthy blood sugar levels, no complications, and a good quality of life for the patient afflicted with diabetes.The China diabetes treatment industry is the largest in the world and has the greatest growth rate. China is the largest country in the world for diabetes cases because of factors like increasing urbanization, sedentary lifestyles, and unhealthy diets. Thus, the Chinese government acknowledges the serious health implications of the disease and is initiating some programs to check the burgeoning epidemic.The Chinese diabetes treatment market encompasses oral drugs, insulin, insulin delivery devices, blood glucose monitoring systems, and diabetes education programs. It is also well marked by the growth of demand for innovative therapies, such as GLP-1 receptor agonists and SGLT-2 inhibitors.As more people age and suffer from the disease, the demand for this effective treatment is expected to grow with age. Recent developments include: April 2023: National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., October 2022: Hua Medicine announced that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator developed by the Company, was officially approved by the National Medical Products Administration (NMPA) of China. It is to be used as monotherapy for drug naïve Type 2 diabetes patients or combined with metformin in metformin-tolerated Type 2 diabetes to control blood glucose levels.. Key drivers for this market are: Increasing Geriatric Population and Changing Dietary Habits, High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures. Potential restraints include: Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs, Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs. Notable trends are: The oral anti-diabetic drugs segment holds the highest market share in the China Diabetes Care Drugs Market in the current year.

The China insulin drugs and delivery devices market is experiencing steady growth, projected to reach a market size of $6.20 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 2.60% from 2019 to 2033. This growth is fueled by several key factors. The rising prevalence of diabetes, particularly type 2 diabetes, in China's increasingly aging and urbanizing population is a major driver. Improved healthcare infrastructure and increasing awareness of diabetes management are also contributing to market expansion. Furthermore, technological advancements in insulin delivery devices, such as the development of more convenient and user-friendly systems like insulin pens and pumps, are driving adoption. Government initiatives focused on improving diabetes care and expanding access to affordable medications further support market growth. However, challenges remain, including high treatment costs that can limit access for a significant portion of the population, particularly in rural areas. The complexity of managing diabetes and the need for consistent patient education also pose hurdles to widespread treatment adoption. Despite these constraints, the market's positive trajectory is expected to continue, driven by the underlying demographic trends and advancements in both drug therapies and delivery technologies. Competition is fierce, with major players like Ypsomed, Medtronic, Novo Nordisk, Eli Lilly, Sanofi, and Becton Dickinson vying for market share. The market's segmentation includes insulin drugs and delivery devices, with both segments expected to experience robust growth over the forecast period. The market's projected growth is underpinned by ongoing research and development in novel insulin analogs and delivery systems. Companies are investing heavily in developing more effective, safer, and easier-to-use insulin formulations and delivery devices. This innovation is a key factor in enhancing patient compliance and improving diabetes management outcomes. Furthermore, the growing focus on personalized medicine and the development of tailored treatment strategies based on individual patient needs is expected to propel market expansion. The increasing integration of digital health technologies into diabetes management, such as connected insulin pumps and remote monitoring systems, will further contribute to market growth. The competitive landscape is anticipated to remain dynamic, with continued consolidation and strategic partnerships amongst existing players and the potential emergence of new entrants. Successful players will need to focus on innovation, affordability, and robust distribution networks to capture a significant market share in this evolving and increasingly competitive market. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: Rising diabetes prevalence.

The Danish pharmaceutical company Novo Nordisk's insulin product Novomix® ** FlexPen® has been the bestselling antidiabetic medication in China. The diabetes medication market in China is dominated by products developed by international pharmaceutical giants.

The China Diabetes Drugs and Devices Market size was valued at USD 12.34 Billion in 2024 and is projected to reach USD 14.10 Billion by 2032, growing at a CAGR of 1.68% from 2026 to 2032.

China Diabetes Drugs and Devices Market Drivers

Rising Prevalence of Diabetes: China is the global hub of the diabetes epidemic, with over 116 million adults affected. This surge, fueled by unhealthy diets, sedentary lifestyles, and urbanization, is boosting demand for diabetes drugs and monitoring devices. This presents a significant opportunity for pharmaceutical companies and device manufacturers, leading to increased government and private investments in diabetes care solutions.

Aging Population and Increasing Life Expectancy: China's aging population is driving a rise in chronic diseases, including diabetes, primarily affecting older individuals. The National Health Commission reports a sharp increase in diabetes incidence among those over 60, emphasizing the need for advanced treatments and monitoring tools. The combination of an aging population and longer life expectancy leads to a sustained demand for diabetes management solutions, including insulin therapy and glucose monitoring devices.

Government Healthcare Reforms and Policy Support: The Chinese government has implemented policies to enhance healthcare access, notably affecting the diabetes drugs and devices market. The National Health Commission has integrated diabetes care into the healthcare system, offering more affordable treatments. The inclusion of diabetes drugs in the National Reimbursement Drug List has reduced patient costs. Government support for the Affordable Healthcare for All initiative and health insurance coverage for diabetes management is also driving market growth by promoting broader access to essential treatments and devices.

China was valued above 10.98 billion US dollars in 2024 due to rising diabetes cases and tech-driven therapy adherence tools.

China Diabetes Devices Market size was valued at USD 2.69 Billion in 2023 and is projected to reach USD 4.87 Billion by 2031, growing at a CAGR of 7.7% from 2024 to 2031.

China Diabetes Devices Market Dynamics

The key market dynamics that are shaping the China Diabetes Devices Market include:

Key Market Drivers Growing Diabetes Prevalence in China: According to the International Diabetes Federation, China has the world's largest number of adults with diabetes, with around 141.8 million affected in 2021. The National Health Commission reported an 11.2% diabetes prevalence among adults, highlighting the vital significance of enhanced diabetes care solutions.

The China Continuous Glucose Monitoring (CGM) Devices market is experiencing robust growth, projected to reach a market size of $505.13 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 10.39% from 2025 to 2033. This expansion is fueled by several key factors. Firstly, the rising prevalence of diabetes in China, coupled with increasing awareness of the benefits of CGM technology for improved blood sugar management and reduced complications, is driving significant demand. Secondly, advancements in CGM technology, including smaller, more user-friendly devices with improved accuracy and longer battery life, are making them more accessible and appealing to patients. Government initiatives promoting better diabetes care and the expansion of healthcare infrastructure further contribute to market growth. Competition is intense, with key players such as Abbott Diabetes Care, Dexcom Inc., and Medtronic PLC holding significant market share, but also facing challenges from emerging domestic companies like Yuwell and Jiunuo Medical. The market segmentation shows a strong demand for both sensor and durable components of CGM systems. Future growth will likely depend on continued technological innovation, pricing strategies that improve affordability, and successful partnerships between manufacturers and healthcare providers to improve patient access and education. The continued high CAGR suggests substantial growth potential in the coming years. While challenges remain, such as the need for increased affordability and healthcare system integration, the long-term outlook for the China CGM market remains positive. The focus will be on expanding market penetration among the large diabetic population, particularly in underserved regions, and increasing the adoption of CGM technology within the Chinese healthcare system. The success of domestic companies will significantly influence the overall market dynamics. The market segmentation, with a focus on both sensor and durable components, indicates opportunities for specialized manufacturers and further innovation within these segments. Recent developments include: November 2023: SIBIONICS, a Chinese company, announced that it received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, facilitating the distribution and utilization of this game-changing technology throughout the European market., June 2023: Medical diagnostic company Know Labs is aiming to release the world’s first commercially available non-invasive glucose monitor with the launch of its Generation (Gen) 1 device. The device houses the company’s Bio-RFID technology, which was shown to consistently and accurately measure glucose levels non-invasively in a feasibility study conducted by the Washington, US-based company across late 2022 and early 2023.. Notable trends are: Rising Diabetes Prevalence in China.

The China Diabetes Drugs and Devices market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

In 2018, the market size of Chinese diabetes medication sector was estimated to be about 51.8 billion yuan with oral hypoglycemic drugs as the major revenue generator. Its market share would gradually decline, whereas glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were expected to raise its market presence significantly to 21 percent by 2030. In 2017, Beijing included Novo Nordisk's Liragultide - the bestselling GLP-1 RA medication in China - into the national insurance list for reimbursement, leading to a surge in sales revenue of the product in the country.